Abbott India Limited (NSE: ABBOTINDIA.NS) Stock Competitors & Peer Comparison

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ABBOTINDIA.BO has a market cap of 556.1B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ABBOTINDIA.BO trades at ₹26,154.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ABBOTINDIA.BO's P/E ratio is 35.32. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to ABBOTINDIA.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ABBOTINDIA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check JBCHEPHARM.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check JBCHEPHARM.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, WOCKPHARMA.NS has a market cap of 317.7B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while WOCKPHARMA.NS trades at ₹1,954.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas WOCKPHARMA.NS's P/E ratio is 77.67. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to WOCKPHARMA.NS's ROE of +0.08%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to WOCKPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check WOCKPHARMA.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, WOCKPHARMA.BO has a market cap of 315.8B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while WOCKPHARMA.BO trades at ₹1,949.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas WOCKPHARMA.BO's P/E ratio is 77.44. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to WOCKPHARMA.BO's ROE of +0.08%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to WOCKPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check WOCKPHARMA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, MEDPLUS.NS has a market cap of 73.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while MEDPLUS.NS trades at ₹611.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas MEDPLUS.NS's P/E ratio is 33.11. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MEDPLUS.NS's ROE of +0.11%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to MEDPLUS.NS. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MEDPLUS.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, MEDPLUS.BO has a market cap of 73.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while MEDPLUS.BO trades at ₹611.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas MEDPLUS.BO's P/E ratio is 32.51. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to MEDPLUS.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MEDPLUS.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SUPRIYA.BO has a market cap of 71.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SUPRIYA.BO trades at ₹885.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SUPRIYA.BO's P/E ratio is 35.91. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SUPRIYA.BO's ROE of +0.17%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SUPRIYA.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SUPRIYA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SUPRIYA.NS has a market cap of 71.3B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SUPRIYA.NS trades at ₹886.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SUPRIYA.NS's P/E ratio is 34.08. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SUPRIYA.NS's ROE of +0.17%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SUPRIYA.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SUPRIYA.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SANOFI.NS has a market cap of 67.8B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SANOFI.NS trades at ₹2,942.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SANOFI.NS's P/E ratio is 19.38. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SANOFI.NS's ROE of +0.41%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SANOFI.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SANOFI.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SANOFI.BO has a market cap of 67.7B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SANOFI.BO trades at ₹2,941.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SANOFI.BO's P/E ratio is 19.38. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SANOFI.BO's ROE of +0.41%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SANOFI.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SANOFI.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, KPL.BO has a market cap of 35.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while KPL.BO trades at ₹3,396.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas KPL.BO's P/E ratio is 43.49. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to KPL.BO's ROE of +0.26%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to KPL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check KPL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SHUKRAPHAR.BO has a market cap of 30.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SHUKRAPHAR.BO trades at ₹68.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SHUKRAPHAR.BO's P/E ratio is 89.02. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SHUKRAPHAR.BO's ROE of +0.44%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SHUKRAPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SHUKRAPHAR.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, HIKAL.NS has a market cap of 26.6B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while HIKAL.NS trades at ₹215.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas HIKAL.NS's P/E ratio is 15.44. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to HIKAL.NS's ROE of -0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to HIKAL.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check HIKAL.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, HIKAL.BO has a market cap of 26.6B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while HIKAL.BO trades at ₹215.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas HIKAL.BO's P/E ratio is 187.35. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to HIKAL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check HIKAL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, FREDUN.BO has a market cap of 24.4B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while FREDUN.BO trades at ₹1,477.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas FREDUN.BO's P/E ratio is 58.13. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to FREDUN.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check FREDUN.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ACCENTMIC.NS has a market cap of 16.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ACCENTMIC.NS trades at ₹675.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ACCENTMIC.NS's P/E ratio is 28.47. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ACCENTMIC.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ACCENTMIC.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, VIKRAMTH.BO has a market cap of 12.6B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while VIKRAMTH.BO trades at ₹401.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas VIKRAMTH.BO's P/E ratio is 28.70. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to VIKRAMTH.BO's ROE of +0.30%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check VIKRAMTH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, BPLPHARMA.BO has a market cap of 12.4B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while BPLPHARMA.BO trades at ₹1,803.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas BPLPHARMA.BO's P/E ratio is -80.64. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to BPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check BPLPHARMA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, REMUS.NS has a market cap of 11.8B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while REMUS.NS trades at ₹1,002.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas REMUS.NS's P/E ratio is 31.92. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to REMUS.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check REMUS.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, BAFNAPH.BO has a market cap of 10.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while BAFNAPH.BO trades at ₹468.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas BAFNAPH.BO's P/E ratio is 142.39. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to BAFNAPH.BO's ROE of +0.08%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to BAFNAPH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check BAFNAPH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, BAFNAPH.NS has a market cap of 10.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while BAFNAPH.NS trades at ₹461.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas BAFNAPH.NS's P/E ratio is 140.17. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to BAFNAPH.NS's ROE of +0.08%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to BAFNAPH.NS. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check BAFNAPH.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ONEGLOBAL.BO has a market cap of 10.7B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ONEGLOBAL.BO trades at ₹549.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ONEGLOBAL.BO's P/E ratio is 14.54. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ONEGLOBAL.BO's ROE of +0.61%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ONEGLOBAL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ONEGLOBAL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SUDARSHAN.BO has a market cap of 9.1B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SUDARSHAN.BO trades at ₹36.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SUDARSHAN.BO's P/E ratio is 34.36. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SUDARSHAN.BO's ROE of +0.17%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SUDARSHAN.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SUDARSHAN.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SASTASUNDR.NS trades at ₹282.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SASTASUNDR.NS's ROE of -0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SASTASUNDR.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SGRL.BO has a market cap of 8.8B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SGRL.BO trades at ₹687.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SGRL.BO's P/E ratio is 57.16. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SGRL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SGRL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ALBERTDA.BO trades at ₹1,084.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ALBERTDA.BO's ROE of +0.06%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ALBERTDA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PRAVEG.BO has a market cap of 6B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PRAVEG.BO trades at ₹230.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PRAVEG.BO's P/E ratio is -31.91. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PRAVEG.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PRAVEG.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, TRANSCHEM.BO has a market cap of 5.1B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while TRANSCHEM.BO trades at ₹414.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas TRANSCHEM.BO's P/E ratio is 109.97. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to TRANSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TRANSCHEM.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, TLL.BO has a market cap of 5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while TLL.BO trades at ₹419.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas TLL.BO's P/E ratio is 23.45. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to TLL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TLL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, INFINIUM.NS has a market cap of 4.8B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while INFINIUM.NS trades at ₹305.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas INFINIUM.NS's P/E ratio is 39.12. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to INFINIUM.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check INFINIUM.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, JENBURPH.BO has a market cap of 4B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while JENBURPH.BO trades at ₹916.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas JENBURPH.BO's P/E ratio is 12.31. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to JENBURPH.BO's ROE of +0.17%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to JENBURPH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check JENBURPH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, AMBALALSA.BO has a market cap of 2.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while AMBALALSA.BO trades at ₹38.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas AMBALALSA.BO's P/E ratio is 21.56. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to AMBALALSA.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check AMBALALSA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ZENOTECH.BO has a market cap of 2.6B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ZENOTECH.BO trades at ₹43.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ZENOTECH.BO's P/E ratio is -104.41. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ZENOTECH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ZENOTECH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, BDH.BO has a market cap of 2.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while BDH.BO trades at ₹440.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas BDH.BO's P/E ratio is 21.64. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to BDH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check BDH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, GENNEX.BO has a market cap of 2.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while GENNEX.BO trades at ₹9.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas GENNEX.BO's P/E ratio is 11.14. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GENNEX.BO's ROE of +0.08%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GENNEX.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SANJIVIN.BO has a market cap of 2.1B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SANJIVIN.BO trades at ₹174.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SANJIVIN.BO's P/E ratio is 29.16. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SANJIVIN.BO's ROE of +0.16%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SANJIVIN.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SANJIVIN.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, CORALAB.BO has a market cap of 1.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while CORALAB.BO trades at ₹533.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas CORALAB.BO's P/E ratio is 9.93. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to CORALAB.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check CORALAB.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, KERALAYUR.BO has a market cap of 1.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while KERALAYUR.BO trades at ₹146.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas KERALAYUR.BO's P/E ratio is -6.90. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to KERALAYUR.BO's ROE of -2.62%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to KERALAYUR.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check KERALAYUR.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SYSCHEM.BO has a market cap of 1.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SYSCHEM.BO trades at ₹34.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SYSCHEM.BO's P/E ratio is 579.50. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SYSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SYSCHEM.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, OXYGENTAPH.BO has a market cap of 1.7B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while OXYGENTAPH.BO trades at ₹47.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas OXYGENTAPH.BO's P/E ratio is -12.80. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to OXYGENTAPH.BO's ROE of +0.34%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check OXYGENTAPH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SMRUTHIORG.BO has a market cap of 1.7B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SMRUTHIORG.BO trades at ₹147.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SMRUTHIORG.BO's P/E ratio is 22.76. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SMRUTHIORG.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SMRUTHIORG.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, KIMIABL.BO has a market cap of 1.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while KIMIABL.BO trades at ₹32.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas KIMIABL.BO's P/E ratio is 21.14. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to KIMIABL.BO's ROE of +0.49%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to KIMIABL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check KIMIABL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, QUESTLAB.NS has a market cap of 1.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while QUESTLAB.NS trades at ₹92.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas QUESTLAB.NS's P/E ratio is 10.06. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to QUESTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check QUESTLAB.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, AUROLAB.BO has a market cap of 1.4B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while AUROLAB.BO trades at ₹226.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas AUROLAB.BO's P/E ratio is 30.18. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to AUROLAB.BO's ROE of +0.10%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to AUROLAB.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check AUROLAB.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PANCHSHEEL.BO has a market cap of 1.4B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PANCHSHEEL.BO trades at ₹106.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PANCHSHEEL.BO's P/E ratio is 12.90. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PANCHSHEEL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PANCHSHEEL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, GODAVARI.BO has a market cap of 1.4B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while GODAVARI.BO trades at ₹133.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas GODAVARI.BO's P/E ratio is 30.67. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GODAVARI.BO's ROE of +0.07%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to GODAVARI.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GODAVARI.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, LACTOSE.BO has a market cap of 1.3B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while LACTOSE.BO trades at ₹106.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas LACTOSE.BO's P/E ratio is 19.26. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to LACTOSE.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check LACTOSE.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PARNAXLAB.BO has a market cap of 1.3B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PARNAXLAB.BO trades at ₹115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PARNAXLAB.BO's P/E ratio is 14.76. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PARNAXLAB.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PARNAXLAB.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, MAKERSL.BO has a market cap of 1.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while MAKERSL.BO trades at ₹207.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas MAKERSL.BO's P/E ratio is 35.78. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to MAKERSL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MAKERSL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while TYCHE.BO trades at ₹105.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas TYCHE.BO's P/E ratio is 24.53. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to TYCHE.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TYCHE.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PHARMAID.BO trades at ₹30.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PHARMAID.BO's P/E ratio is -23.32. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PHARMAID.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SOTAC.NS has a market cap of 995.1M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SOTAC.NS trades at ₹90.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SOTAC.NS's P/E ratio is 17.24. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to SOTAC.NS. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SOTAC.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, MERCURYLAB.BO has a market cap of 906M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while MERCURYLAB.BO trades at ₹755.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas MERCURYLAB.BO's P/E ratio is 21.76. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to MERCURYLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MERCURYLAB.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, DENISCHEM.BO has a market cap of 860.4M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while DENISCHEM.BO trades at ₹62.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas DENISCHEM.BO's P/E ratio is 10.78. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to DENISCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check DENISCHEM.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, VAISHALI.NS has a market cap of 837.2M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while VAISHALI.NS trades at ₹7.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas VAISHALI.NS's P/E ratio is 24.33. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to VAISHALI.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check VAISHALI.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, CONCORD.BO has a market cap of 767.4M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while CONCORD.BO trades at ₹68.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas CONCORD.BO's P/E ratio is 41.13. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to CONCORD.BO's ROE of +0.05%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to CONCORD.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check CONCORD.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, VILINBIO.NS has a market cap of 742.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while VILINBIO.NS trades at ₹53.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas VILINBIO.NS's P/E ratio is 41.79. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to VILINBIO.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check VILINBIO.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SOURCENTRL.BO has a market cap of 726.4M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SOURCENTRL.BO trades at ₹112.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SOURCENTRL.BO's P/E ratio is 21.37. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SOURCENTRL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SOURCENTRL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SUNLOC.BO has a market cap of 717.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SUNLOC.BO trades at ₹70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SUNLOC.BO's P/E ratio is 20.16. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SUNLOC.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SUNLOC.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ZENITHDRUG.NS has a market cap of 710M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ZENITHDRUG.NS trades at ₹40.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ZENITHDRUG.NS's P/E ratio is 18.00. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ZENITHDRUG.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ZENITHDRUG.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PHRMASI.BO has a market cap of 546.2M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PHRMASI.BO trades at ₹80.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PHRMASI.BO's P/E ratio is 3.11. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PHRMASI.BO's ROE of +1.07%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PHRMASI.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PHRMASI.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SHELTER.BO has a market cap of 531M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SHELTER.BO trades at ₹45.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SHELTER.BO's P/E ratio is 8.50. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SHELTER.BO's ROE of +0.13%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SHELTER.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SHELTER.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PARMAX.BO has a market cap of 515.4M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PARMAX.BO trades at ₹137.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PARMAX.BO's P/E ratio is -44.72. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PARMAX.BO's ROE of +0.22%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to PARMAX.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PARMAX.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ANG.BO has a market cap of 493.3M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ANG.BO trades at ₹37.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ANG.BO's P/E ratio is -3.70. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ANG.BO's ROE of -0.23%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ANG.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ANG.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, VRL.BO has a market cap of 444.2M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while VRL.BO trades at ₹139.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas VRL.BO's P/E ratio is 7.67. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to VRL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check VRL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, BIBCL.BO has a market cap of 427.9M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while BIBCL.BO trades at ₹9.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas BIBCL.BO's P/E ratio is -3.92. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to BIBCL.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check BIBCL.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, VISTAPH.BO has a market cap of 385.9M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while VISTAPH.BO trades at ₹6.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas VISTAPH.BO's P/E ratio is -3.25. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check VISTAPH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, MEDIORG.NS has a market cap of 380M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while MEDIORG.NS trades at ₹26.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas MEDIORG.NS's P/E ratio is -7.84. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to MEDIORG.NS. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MEDIORG.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ROOPAIND.BO has a market cap of 349.3M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ROOPAIND.BO trades at ₹44.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ROOPAIND.BO's P/E ratio is 341.62. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ROOPAIND.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SANDUPHQ.BO has a market cap of 344.5M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SANDUPHQ.BO trades at ₹35.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SANDUPHQ.BO's P/E ratio is 19.59. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SANDUPHQ.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SANDUPHQ.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PANJON.BO has a market cap of 335.1M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PANJON.BO trades at ₹19.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PANJON.BO's P/E ratio is 122.00. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PANJON.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, MEDICAPQ.BO has a market cap of 324.1M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while MEDICAPQ.BO trades at ₹25.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas MEDICAPQ.BO's P/E ratio is -18.22. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to MEDICAPQ.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MEDICAPQ.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, DECCAN.BO has a market cap of 319.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while DECCAN.BO trades at ₹12.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas DECCAN.BO's P/E ratio is 12.67. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to DECCAN.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check DECCAN.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, BACPHAR.BO has a market cap of 307.3M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while BACPHAR.BO trades at ₹21.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas BACPHAR.BO's P/E ratio is 71.71. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to BACPHAR.BO's ROE of +0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to BACPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check BACPHAR.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, GUJTERC.BO has a market cap of 285.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while GUJTERC.BO trades at ₹36.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas GUJTERC.BO's P/E ratio is 13.24. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GUJTERC.BO's ROE of +0.24%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to GUJTERC.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GUJTERC.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while TRIMURTHI.BO trades at ₹26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TRIMURTHI.BO's ROE of +0.10%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to TRIMURTHI.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TRIMURTHI.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, WELCURE.BO has a market cap of 247.2M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while WELCURE.BO trades at ₹0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas WELCURE.BO's P/E ratio is -9.94. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check WELCURE.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ISHITADR.BO has a market cap of 217.4M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ISHITADR.BO trades at ₹72.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ISHITADR.BO's P/E ratio is 30.78. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to ISHITADR.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ISHITADR.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while CHEMOPH.BO trades at ₹130.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to CHEMOPH.BO's ROE of +0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check CHEMOPH.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ZENLABS.BO has a market cap of 180.3M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ZENLABS.BO trades at ₹27.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ZENLABS.BO's P/E ratio is -7.38. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ZENLABS.BO's ROE of -0.27%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to ZENLABS.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ZENLABS.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, COLINZ.BO has a market cap of 176.3M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while COLINZ.BO trades at ₹70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas COLINZ.BO's P/E ratio is 6.31. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to COLINZ.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check COLINZ.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SUNREST.NS has a market cap of 161.6M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SUNREST.NS trades at ₹37.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SUNREST.NS's P/E ratio is 4.34. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SUNREST.NS. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SUNREST.NS's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, NORRIS.BO has a market cap of 153.3M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while NORRIS.BO trades at ₹15.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to NORRIS.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check NORRIS.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, SHAMROIN.BO has a market cap of 147.9M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while SHAMROIN.BO trades at ₹27.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas SHAMROIN.BO's P/E ratio is -13.79. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SHAMROIN.BO's ROE of -1.27%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to SHAMROIN.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SHAMROIN.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, BERLDRG.BO has a market cap of 120.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while BERLDRG.BO trades at ₹23.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas BERLDRG.BO's P/E ratio is 19.34. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to BERLDRG.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check BERLDRG.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, EMMESSA.BO has a market cap of 109M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while EMMESSA.BO trades at ₹21.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas EMMESSA.BO's P/E ratio is 26.94. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to EMMESSA.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check EMMESSA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, KOBO.BO has a market cap of 103.6M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while KOBO.BO trades at ₹4.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas KOBO.BO's P/E ratio is -1.59. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to KOBO.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check KOBO.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, ADLINE.BO has a market cap of 92.4M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while ADLINE.BO trades at ₹15.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to ADLINE.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ADLINE.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, TRINITYLEA.BO has a market cap of 77.5M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while TRINITYLEA.BO trades at ₹9.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas TRINITYLEA.BO's P/E ratio is -57.59. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TRINITYLEA.BO's ROE of -0.05%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to TRINITYLEA.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TRINITYLEA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, GANGAPHARM.BO has a market cap of 73.9M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while GANGAPHARM.BO trades at ₹12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas GANGAPHARM.BO's P/E ratio is 73.53. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to GANGAPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GANGAPHARM.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, HINDBIO.BO has a market cap of 72.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while HINDBIO.BO trades at ₹7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas HINDBIO.BO's P/E ratio is -35.32. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to HINDBIO.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check HINDBIO.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, VIVANZA.BO has a market cap of 68M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while VIVANZA.BO trades at ₹1.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas VIVANZA.BO's P/E ratio is 14.96. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to VIVANZA.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check VIVANZA.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while TIAANC.BO trades at ₹6.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TIAANC.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, DECIPHER.BO has a market cap of 55.8M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while DECIPHER.BO trades at ₹5.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas DECIPHER.BO's P/E ratio is -1.83. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to DECIPHER.BO. This indicates lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check DECIPHER.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, TMTIND-B1.BO has a market cap of 43.9M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while TMTIND-B1.BO trades at ₹8.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas TMTIND-B1.BO's P/E ratio is -177.40. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to TMTIND-B1.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TMTIND-B1.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while FABINO.BO trades at ₹20.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to FABINO.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check FABINO.BO's competition here

Abbott India Limited (NSE: ABBOTINDIA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABBOTINDIA.NS stands at 556.1B. In comparison, PATIDAR.BO has a market cap of 34M. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹26,170.00 on the NSE, while PATIDAR.BO trades at ₹6.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABBOTINDIA.NS currently has a P/E ratio of 35.34, whereas PATIDAR.BO's P/E ratio is -14.71. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PATIDAR.BO's ROE of -0.03%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to PATIDAR.BO. This indicates higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PATIDAR.BO's competition here